ABSTRACT: Older women are often the most challenging group of patients in fertility clinics due to a decline in both number and overall quality of oocytes. The quality of oocytes has been linked to mitochondrial dysfunction. In this mini-review, we discuss this hypothesis and suggest alternative treatment options using autologous mitochondria to potentially augment pregnancy potential in ART. Autologous transfer of mitochondria from the patient's own germline cells has attracted much attention as a possible new treatment to revitalize deficient oocytes. IVF births have been reported after transfer of oogonial precursor cell-derived mitochondria; however, the source and quality of the mitochondria are still unclear. In contrast, fully grown oocytes are loaded with mitochondria which have passed the genetic bottleneck and are likely to be of high quality. An increased supply of such oocytes could potentially be obtained by in vitro follicle activation of ovarian cortical biopsies or from surplus immature oocytes collected from women undergoing ART or fertility preservation of ovarian tissue. Taken together, autologous oocytes are not necessarily a limiting resource in ART as fully grown oocytes with high quality mitochondria can be obtained from natural or stimulated ovaries and potentially be used to improve both quality and quantity of oocytes available for fertility treatment.
Introduction
Many women in most high-income countries postpone childbearing until their thirties and forties (Mills et al., 2011) . However, female fecundity decreases with age, and the decline accelerates rapidly after 35 years of age (Menken et al., 1986; Nelson et al., 2013) . Moreover, an age-dependent decline in the quality of oocytes occurs, mainly due to an increase in chromosomal aneuploidy of which the prevalence rises dramatically with advanced maternal age (Franasiak et al., 2014) .
Consequently, women of advanced reproductive age are often the most challenging population of patients in fertility centers as these women frequently present both low number and poor quality oocytes resulting in limited reproductive success (Stoop et al., 2012) .
In this mini-review, we discuss alternative treatment options using autologous mitochondria which potentially could augment pregnancy potential of oocytes from women of advanced reproductive age, including novel strategies that simultaneously provide both increased number and augmented quality of mature oocytes.
Mitochondria and oocytes
Mitochondria constitute the powerhouse of cells as they synthesize ATP by oxidative phosphorylation. They possess their own small genome in the form of mitochondrial DNA (mtDNA), but due to the lack of protective histones, introns and DNA-repair enzymes the mtDNA accumulates mutations and deletions to a higher degree than nuclear DNA (Satoh and Kuroiwa, 1991; Bentov and Casper, 2013; Scheibye-Knudsen et al., 2015) . Mitochondria are inherited uniparentally from the mother as sperm mitochondrial proteins are ubiquitinated and degraded after oocyte entry (Kaneda et al., 1995; Song et al., 2014) .
Female germ cells and the genetic bottleneck of mtDNA
Mitochondrial replication starts in the primordial germ cells (PGCs) and continues during early oogenesis; however, a sharp increase in mitochondrial number is observed during later stages of oogenesis (St John, 2014) . Thus, whereas PGCs only contain a few hundred copies of mtDNA, mature oocytes contain up to several hundred thousand copies (Wai et al., 2008; Otten and Smeets, 2015) . The fact that mitochondria on one hand undergo relatively rapid mutations and on the other hand are capable of maintaining an unmodified genome through generations has been explained by a genetic bottleneck theory (Wai et al., 2008; Johnston et al., 2015; reviewed in Mishra and Chan, 2014; Stewart and Chinnery, 2015) , which postulates that only a small proportion of the total number of mitochondrial genomes are passed on from mother to offspring (Hauswirth and Laipis, 1985) . The precise mechanism is not yet well defined, but originally it was thought that in PGCs the bottleneck resulted from selection of mitochondria with normal mtDNA while eliminating mutated mtDNA, which resulted in a more homogenous mtDNA population (Stewart and Chinnery, 2015; May-Panloup et al., 2016) . However, a murine study suggested that selection of mitochondria and mtDNA in the oocyte occurs randomly and no screening for the intact wild-type mitochondrial genome takes place (Inoue et al., 2000) . The selection of mtDNA nucleoids preferentially amplified during replication appears to occur during folliculogenesis and oocyte growth (Wai et al., 2008; Bentov et al., 2011) .
It may be speculated that the actual bottleneck is occurring during fetal life, which is characterized by a massive loss of female germ cells during initiation of meiosis and follicular establishment (Baker, 1963; Gougeon et al., 1994) . Both of these processes are likely to require high energy consumption. Only around 1 in 10 of the oogonia makes it through fetal life and ends up in a functional follicle at birth. Thus, oocytes with preferentially normal mitochondria are likely to be better suited to undertake this process compared to those with abnormal mitochondria and insufficient energy production.
Mitochondria are major factors of oocyte quality
Mitochondria play vital roles in oocyte functions and are the major source of ATP during preimplantation embryonic development as glycolysis is limited after fertilization and mitochondrial replication is suppressed from metaphase II (MII) oocytes until the hatched blastocyst stage (Chappel, 2013) .
Dysfunction of oocyte mitochondria is believed to be a key factor involved in poor developmental competence of oocytes in older infertility patients (Babayev and Seli, 2015) . The mtDNA content in oocytes of reproductive aged women or of women with diminished ovarian reserve is significantly lower than that of younger patients or those with normal ovarian reserve (Duran et al., 2011; Murakoshi et al., 2013) . Furthermore, mtDNA content correlates with the ability of human oocytes to be fertilized as oocytes that remain unfertilized possess lower mtDNA copy number (Reynier et al., 2001; Santos et al., 2006) . However, mitochondrial copy number does not seem to be crucial for oocyte maturation and fertilization in pigs and mice as alterations in mtDNA copy number only seem to interfere with embryo development (Ge et al., 2012; Lee et al., 2014) . In humans, higher ATP levels in oocytes correlate with better embryo development and implantation rates (Van Blerkom et al., 1995) , thus it has been suggested that oocytes during maturation contain excessive amounts of mitochondria with the primary aim of supporting early embryonic development where mitochondrial replication is suppressed (Babayev and Seli, 2015) .
Attenuated mitochondrial activity reduces the production of ATP, and failure of ATP production has been shown to have deleterious consequences on chromosome segregation and on embryonic development which could potentially lead to aneuploid embryos and reduced implantation (Van Blerkom, 2011; Eichenlaub-Ritter, 2012) .
Fertility treatments using heterologous sources of mitochondria
Both pharmacological approaches and cytoplasmic-, nuclear-and mitochondrial transfer have been used to exchange and enhance the integrity, activity and number of mitochondria in quality-compromised oocytes.
In the 1990s, cytoplasmic transfer, or the augmentation of patient oocytes with a small volume (1-5%) of ooplasm from young donors was used by several IVF clinics in an effort to overcome repeated IVF failures in selected patients (Cohen et al., 1998; Barritt et al., 2001) . The procedure essentially involved co-injection of donor ooplasm with sperm during ICSI. Heterologous ooplasmic transfer led to successful pregnancies with almost 50 live births. However, donor mtDNA was identified in the offspring ('three genetic parents') which raised both ethical and genetic questions and the procedure was suspended by the US Food and Drug Administration (FDA) in 2002 and remains so.
Mitochondrial manipulations involving the transfer of nuclear DNA have also been developed and were initially proposed to prevent vertical transmission of diseases caused by mutations in mtDNA (Craven et al., 2010; Paull et al., 2013) . The procedure comprised removal of nuclear DNA from an unfertilized oocyte of a patient carrying abnormal mitochondria followed by transfer into an enucleated donor oocyte containing assumed healthy mitochondria. This constructed oocyte was subsequently fertilized by ICSI. However, such mitochondrial manipulations have come under criticism worldwide (Isasi et al., 2016) as these techniques raise the risks of heteroplasmy i.e. the coexistence of two mtDNA genomes, linked to the use of mitochondria or ooplasm from a third donor. Intriguingly, non-pathogenic variants of mitochondrial heteroplasmy have been reported to alter physiological and cognitive functions in mice (Acton et al., 2007; Sharpley et al., 2012) . Moreover, even though the nuclear genetic material is contributed by two parents 'only', and the oocyte donor who contributes the mtDNA provides only marginally to the total genetic make-up of the newborn, this cannot distract from the fact that there are three genetic parents. The techniques have therefore been ethically challenged and are currently considered controversial.
Autologous mitochondrial transfer
Injection of purified mitochondria instead of ooplasm is, however, a potential alternative approach to present much larger amounts of mitochondria into the oocyte (Liu et al., 2014) . Simple guidelines for mitochondrial injection demand that the mitochondria should be obtained from the patient's own cells which optimally should be of ovarian or oocyte origin (Ferreira et al., 2010; Takeda et al., 2010; Koopman et al., 2012; Wolf et al., 2015; Darbandi et al., 2016) , and the mtDNA from these cells should have passed the mitochondrial bottleneck and be of high quality, without deletions or mutations (Darbandi et al., 2016) .
Use of autologous mitochondria from ovarian stem cells
The recent suggestion that adult oogonial stem cells (OSCs) might provide a source of patient-matched germline mitochondria to augment oocyte performance launched a new approach. In 2012, it was reported that human OSCs were isolated from cortical biopsies from ovaries of reproductive age women by a Ddx4 (Vasa) antibody-based protocol (White et al., 2012) . Recently, the American company 'OvaScience' reported improved fertility in women with previous poor reproductive performance by autologous mitochondrial injection treatment-also referred to as the AUGMENT SM treatment (Fakih et al., 2015; Woods and Tilly, 2015) . By isolating OSCs from human cortical biopsies, they obtained autologous mitochondria by differential centrifugation. In connection with ICSI, the mitochondria were injected into oocytes to augment oocyte performance. As a result of this procedure, more than a dozen healthy live births or ongoing pregnancies have been reported (Fakih et al., 2015; Meldrum et al., 2016) . However, this procedure has been challenged by the ESHRE SIG Stem Cells group, which have asked for RCT's with a proper control group, and highlighted methodological issues and the lack of information form animal models. Furthermore, it is not yet proven whether these germ cell-derived mitochondria actually have passed the genetic bottleneck and are suitable to pass on to the next generation (Gosden and Johnson, 2016) . The current theory suggests that the mitochondrial bottleneck takes place during folliculogenesis (Wai et al., 2008) which is long after the OSC development takes place.
Alternative approach; improving both oocyte quantity and quality
Since OSCs are difficult to obtain and contain relatively low numbers of mitochondria, alternative sources of oocytes that would have passed the genetic bottleneck and in theory would be loaded with uncompromised mitochondria should be considered. The number of autologous fully grown oocytes may be significantly augmented by in vitro follicle activation (IVA) of ovarian cortical biopsies or by using surplus immature oocytes collected when the woman undergoes ART or fertility preservation of ovarian tissue (Fig. 1) . This alternative approach could potentially enhance the number of oocytes available for fertility treatment but also augment oocyte performance by autologous mitochondrial injection.
Increasing oocyte quantity by IVA The lipid phosphatase PTEN inhibits the PI3K-AKT signal transduction pathway and acts as a break on follicle activation (Reddy et al., 2008) . In 2013, a Japanese group were the first to test IVA in a clinical setting (Kawamura et al., 2013) . In this study, ovarian cortical tissue from premature ovarian insufficiency patients were activated in vitro using a PTEN inhibitor, bpv(pic), together with an AKT stimulator, and after grafting they found rapid follicle growth in some patients. Mature oocytes were successfully retrieved and have now resulted in three live births in Japan and China and one pregnancy in Spain (Kawamura et al., 2013; Suzuki et al., 2015; Kawamura et al., 2015; Zhai et al., 2016) .
As an alternative, the ovarian biopsy excised for OSCs production could be used for IVA instead (Fig. 1) . Following a short treatment to stimulate PI3K-AKT signaling, ovarian tissue should be transplanted back into the woman-without cryopreservation of the tissue as performed in Japan. Three to six months later, the patient will potentially develop a large cohort of follicles containing fully grown oocytes. These oocytes would be available for ART, but their competence would probably be compromised due to the age of the woman. If this approach results in extended number of mature oocytes, some of these oocytes may be used as a source of mitochondria to augment performance of the remaining cohort of oocytes. Delivery of the mitochondria can be performed in connection with ICSI as previously shown. Thus, this strategy would not only enhance oocyte numbers but also potentially improve oocyte quality, and may represent an alternative strategy especially in women with poor reproductive performance.
However, good evidence for the safe use of IVA in humans are currently lacking as only few studies on human ovarian tissue have been performed and no RCT has yet been conducted. PTEN has a wellknown role as a tumor suppressor and is commonly mutated in human cancer diseases (Cully et al., 2006; Song et al., 2012) . Thus, deletion or inhibition of PTEN could potentially lead to oncogenic transformation of cells in the ovary (Kim et al., 2016) . Moreover, PTEN inhibitors have been shown be unspecific and cytotoxic when used in high (micro-molar) concentrations (Schmid et al., 2004) . However, no toxicity, tumorigenesis or effects on fertility were observed when injecting female mice directly with PTEN inhibitors or in first-and secondgeneration offspring (Li et al., 2010; Adhikari et al., 2012) . Nonetheless, recent human studies have raised concerns about IVA treatment as human follicular survival was severely compromised in in vitro studies and significant deleterious effects were found (LererSerfaty et al., 2013; McLaughlin et al., 2014) . Therefore, potential tumorigenic effects of PTEN inhibition should thoroughly be tested in animal models, preferentially non-human primates, before applied in a clinical setting. Different targets of the PI3K-AKT and other signaling pathways are now being investigated as potential new candidates for IVA to establish more safe, reproducible and valid methods (Cheng et al., 2015a,b; Sun et al., 2015; Saatcioglu et al., 2016) .
IVM oocytes available in connection with ovarian tissue freezing and ART
Cryopreservation of ovarian tissue differs from conventional oocyte and embryo cryopreservation by restoring the ovarian organ function (von Wolff et al., 2009) . Current practice usually involves the excision of one ovary and the cortical tissue with its dense population of resting primordial follicles is frozen (Rosendahl et al., 2011) . A number of studies have shown that immature oocytes can be collected from antral follicles visible on the surface of the ovary or released to the dissection medium during preparation of the tissue ( Fig. 2A and B ) (Wilken-Jensen et al., 2014; Yin et al., 2016) . These oocytes may be matured, vitrified and used to augment fertility to the patient herself (Fasano et al., 2011; Gonzalez et al., 2011; Imesch et al., 2013; Yin et al., 2016) . The first two successful pregnancies resulting from cryopreserved embryos obtained from in vitro matured (IVM) oocytes collected after oophorectomy were recently reported (Prasath et al., 2014; Segers et al., 2015) . In a recent study, we demonstrated that surprisingly many immature oocytes can be retrieved during the process of ovarian cortex preparation (Fig. 2C) (Yin et al., 2016) . On average, 11 oocytes were collected per patient, ranging from 0 to 43, and 30% of the oocytes matured to the MII stage. The remaining oocytes or potentially all these fully grown oocytes may serve as an autologous source of mitochondria to augment deficient oocytes (Fig. 1) . Isolated cryo-stored mitochondria could be used in subsequent IVF treatment following oocyte collection after transplantation of frozen/thawed ovarian tissue. Furthermore, these IVM oocytes are from unstimulated ovaries and they have a fairly high maturation rate (Yin et al., 2016) , which suggest that they are healthier than immature oocytes from stimulated IVF cycles.
Traditional IVF regimes use gonadotrophins to stimulate the development of a large number of follicles, and oocytes are then recovered by transvaginal ultrasound-guided follicle aspiration, 34-36 h after hCG administration. Only those oocytes that reach MII are used for conventional IVF. However, between 5 and 20% of recovered oocytes are immature (Cha and Chian, 1998) and are usually discarded due to attenuated developmental competence. These immature oocytes may be compromised, but the mitochondria have passed the genetic bottleneck and may represent a new unexploited source of mitochondria to improve oocyte performance in ART (Fig. 1) . In addition, small antral follicles with diameters <12-14 mm may even represent an extra source of immature oocytes that is currently not aspirated in connection with IVF and which may be used to prepare mitochondria. 
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Finding the balance
Constant maintenance of a healthy mitochondrial pool is necessary for normal aging and depends on a precisely coordinated balance of mitochondrial biogenesis and selective cellular degradation. While too few mitochondria impede generation of energy, too many mitochondria also compromise cellular function (Ylikallio et al., 2010) . This might be reflected in a recent study showing that mtDNA levels are higher in embryos from reproductive aged women, in aneuploid embryos (independent of age) and in euploid blastocysts that failed to implant (Fragouli et al., 2015) . Thus, this study is in contrast to the studies showing that a high level of mtDNA content improve oocyte maturation and fertilization (Reynier et al., 2001; Santos et al., 2006) . Therefore, the relationship between mtDNA content, female age, oocyte maturation, fertilization and embryo development warrants further investigations to elucidate the precise role of mitochondria in reproduction. Moreover, the movement of mitochondria to high energy consumption areas is crucial for oocyte maturation (Dumollard et al., 2006; Mao et al., 2014) . In immature oocytes, mitochondria are aggregated around the germinal vesicle (GV) and usually absent from the cortical part of the cytoplasm (Sathananthan and Trounson, 2000; Familiari et al., 2006) , whereas in MI and MII oocytes mitochondria become more numerous and are spread out in the ooplasm (Motta et al., 2000; Sathananthan and Trounson, 2000) . Unlike other species, mitochondria of human oocytes form large aggregates with smooth endoplasmic reticulum tubular membranes and vesicles at the end of the maturation process (Motta et al., 2000; Familiari et al., 2006; Mao et al., 2014) . Whether or not isolated donor or autologous mitochondria are actually capable to function properly, establish the necessary physical connections with other organelles and augment oocyte performance in connection with fertility treatment requires further studies.
Finally, proper animal studies and RCTs are needed in order to substantiate the legitimacy of this potential new treatment option. Moreover, a better characterization and understanding of mitochondrial integrity, content and activity from 'natural', IVF and in vitro activated oocytes are required to advance these techniques to clinical practice.
Conclusion
To overcome ethical considerations on genetic origin and the risk of heteroplasmy; transfer of autologous mitochondria from ovarian cells has attracted much attention as a new possible treatment to improve pregnancy potential of deficient oocytes from reproductive aged women. Both OSCs and oocytes from fully grown oocytes are potential sources of autologous mitochondria which could enhance oocyte performance. The advantages of using surplus fully grown oocytes from IVF, IVM or IVA are that they are fairly easy to obtain and would already have passed the mitochondrial genetic bottleneck and are likely to represent high quality mitochondria (Fig. 1) . In contrast, OSCs are difficult to obtain and contain relatively low numbers of mitochondria of unknown quality. If this potential new treatment becomes an option, it is not necessarily appropriate for all women of advanced reproductive age as dysfunctional mitochondria may be one among many factors that cause developmental failure in oocytes of reproductive aged women. Future studies should try to identify a suitable group of patients for whom the transfer of autologous mitochondria would be the most beneficial.
In conclusion, autologous oocytes are not necessarily a limiting resource in ART for women of advanced reproductive age, and high quality mitochondria could potentially be transferred from natural and stimulated surplus fully grown oocytes to revitalize deficient oocytes, thereby both augmenting quantity and quality of the available cohort of oocytes for fertility.
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